1
|
Montella A, Corallo C, Pastorelli M, Capecchi M, Voglino M, Ruocco G, Wolf G, Giordano N. Association between microvascular and macrovascular damage in patients with systemic sclerosis: an upper limb echo-color-doppler and nailfold videocapillaroscopy study. J BIOL REG HOMEOS AG 2020; 33:1897-1902. [PMID: 31908164 DOI: 10.23812/19-192-l] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A Montella
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - C Corallo
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - M Pastorelli
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - M Capecchi
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - M Voglino
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - G Ruocco
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - G Wolf
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - N Giordano
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| |
Collapse
|
2
|
Abstract
The cerebral venous system is an unusual site of thrombosis, with a particularly high incidence in young adults. This incidence has increased in past decades because of the improvement of neuroradiological techniques. Risk factors for cerebral venous sinus thrombosis overlap with those of other venous thromboembolism sites; however, some are specific for this particular anatomical district. Prognosis is favorable in most cases if diagnosis is made rapidly and treatment is promptly initiated, even if acute complications or chronic invalidity still occur in a quarter of patients. The mainstay of treatment is anticoagulation, which is necessary in order to block clot propagation and obtain recanalization. Intracranial bleeding does not contraindicate anticoagulation. Endovascular procedures are reserved for patients with a particularly severe presentation or rapidly declining neurological symptoms despite appropriate anticoagulation, although data from clinical trials are lacking. Specifically, this review addresses the epidemiology, clinical presentation and course, risk factors, and treatment of cerebral venous sinus thrombosis, with a special focus on the pediatric population.
Collapse
Affiliation(s)
- M Capecchi
- A. Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy
| | - M Abbattista
- A. Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy
| | - I Martinelli
- A. Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy
| |
Collapse
|
3
|
Merli M, Alric L, Mannelli L, De Angelis F, Ferrari A, Capecchi M, Pirisi M, Visco C, Piazza F, Loustaud-Ratti V, Goldaniga M, Zancanella M, Cencini E, Marino D, Benanti F, Rumi M, Frigeni M, Gotti M, Sciarra R, Ferretti V, Grossi P, Passamonti F, Bruno R, Arcaini L. DIRECT-ACTING ANTIVIRALS DURING OR AFTER IMMUNO-CHEMOTHERAPY IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Merli
- Hematology; University Hospital Ospedale di Circolo e Fondazione Macchi-ASST Sette Laghi, University of Insubria; Varese Italy
| | - L. Alric
- Internal Medicine and Digestive Diseases; Toulouse 3 University, Unité mixte de recherche 152, Institut de recherche 152, Institut de Récherche pour le Developpement, Hopital Purpan; Toulouse France
| | - L. Mannelli
- Hematology; Azienda Ospedaliera Careggi; Florence Italy
| | - F. De Angelis
- Cellular Biotechnologies and Hematology; Sapienza University of Rome; Rome Italy
| | - A. Ferrari
- Hematology; IRCCS Arcispedale Santa Maria Nuova; Reggio Emilia Italy
| | - M. Capecchi
- Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - M. Pirisi
- Translational Medicine; University of Piemonte Orientale UPO; Novara Italy
| | - C. Visco
- Cell Therapy and Hematology; Ospedale San Bortolo; Vicenza Italy
| | - F. Piazza
- Medicine-Hematology; University of Padova; Padova Italy
| | - V. Loustaud-Ratti
- Hepatology; Centre Hospitalier Universitaire Limoges, U850 INSERM, Université de Limoges; Limoges France
| | - M. Goldaniga
- Hematology; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milan Italy
| | - M. Zancanella
- Hematology and Oncology, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda; Milan Italy
| | - E. Cencini
- Hematology, Azienda Ospedaliera Senese; University of Siena; Siena Italy
| | - D. Marino
- Oncology Unit 1, Veneto Institute of Oncology IOV_IRCCS; Padova Italy
| | - F. Benanti
- Infectious Diseases; University of Catania; Catania Italy
| | - M. Rumi
- Hepatology, Ospedale San Giuseppe IRCCS Multimedica; University of Milan; Milan Italy
| | - M. Frigeni
- Hematology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - M. Gotti
- Hematology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - R. Sciarra
- Hematology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - V. Ferretti
- Molecular Medicine; University of Pavia; Pavia Italy
| | - P. Grossi
- Infectious and Tropical Diseases; University Hospital Ospedale di Circolo e Fondazione Macchi -ASST Sette Laghi, University of Insubria; Varese Italy
| | - F. Passamonti
- Hematology; University Hospital Ospedale di Circolo e Fondazione Macchi-ASST Sette Laghi, University of Insubria; Varese Italy
| | - R. Bruno
- Infectious and Tropical Diseases, Fondazione IRCCS Policlinico San Matteo; University of Pavia; Pavia Italy
| | - L. Arcaini
- Molecular Medicine; University of Pavia; Pavia Italy
| |
Collapse
|
4
|
Di Paolo A, Polillo M, Capecchi M, Cervetti G, Baratè C, Angelini S, Guerrini F, Fontanelli G, Arici R, Ciabatti E, Grassi S, Bocci G, Hrelia P, Danesi R, Petrini M, Galimberti S. The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenomics J 2014; 14:328-35. [PMID: 24589908 DOI: 10.1038/tpj.2014.7] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/18/2013] [Revised: 01/17/2014] [Accepted: 01/31/2014] [Indexed: 12/30/2022]
Abstract
The aim of the study was to investigate any possible influence of polymorphisms of transmembrane transporters human organic cation transporter 1 (hOCT1), ABCB1, ABCG2 on imatinib pharmacokinetics in 33 men and 27 women (median age and range, 56 and 27-79 years, respectively) affected by chronic myeloid leukemia. A population pharmacokinetic analysis was performed to investigate imatinib disposition in every patient and the role of transporter polymorphisms. Results showed that the α1-acid glycoprotein and the c.480C>G genotype of hOCT1 had a significant effect on apparent drug clearance (CL/F) being responsible, respectively, for a 20% and 10% decrease in interindividual variability (IIV) of CL/F (from 50.1 up to 19.6%). Interestingly, 25 patients carrying at least one polymorphic c.480 G allele had a significant lower CL/F value with respect to the 35 c.480CC individuals (mean±s.d., 9.6±1.6 vs 12.1±2.3 l h(-1), respectively; P<0.001). In conclusion, the hOCT1 c.480C>G SNP may significantly influence imatinib pharmacokinetics, supporting further analyses in larger groups of patients.
Collapse
Affiliation(s)
- A Di Paolo
- Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, Pisa, Italy
| | - M Polillo
- Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, Pisa, Italy
| | - M Capecchi
- Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, Pisa, Italy
| | - G Cervetti
- Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, Pisa, Italy
| | - C Baratè
- Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, Pisa, Italy
| | - S Angelini
- Department of Pharmacy and Biotechnology, University of Bologna, Via Irnerio 48, Bologna, Italy
| | - F Guerrini
- Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, Pisa, Italy
| | - G Fontanelli
- Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, Pisa, Italy
| | - R Arici
- Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, Pisa, Italy
| | - E Ciabatti
- Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, Pisa, Italy
| | - S Grassi
- Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, Pisa, Italy
| | - G Bocci
- 1] Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, Pisa, Italy [2] Istituto Toscano Tumori, Via Alderotti 86/N, Florence, Italy
| | - P Hrelia
- Department of Pharmacy and Biotechnology, University of Bologna, Via Irnerio 48, Bologna, Italy
| | - R Danesi
- Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, Pisa, Italy
| | - M Petrini
- Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, Pisa, Italy
| | - S Galimberti
- Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, Pisa, Italy
| |
Collapse
|
5
|
Strandberg LS, Cui X, Rath A, Liu X, Silverman ED, Siragam V, Ackerley C, Su BB, Yan JY, Capecchi M, Biavati L, Accorroni A, Yuen W, Quattrone F, Lung K, Jaeggi ET, Deber CM, Hamilton RM. SAT0435 A1G T-Type Calcium Channel is Expressed in Human Fetal Hearts and Has an Extracellular Epitope Bound by Autoantibodies from Congenital Heart Block Maternal Sera. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
6
|
Cole J, Ertoy D, Lin H, Sutliff RL, Ezan E, Guyene TT, Capecchi M, Corvol P, Bernstein KE. Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest 2000; 106:1391-8. [PMID: 11104792 PMCID: PMC381466 DOI: 10.1172/jci10557] [Citation(s) in RCA: 128] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
While nephrologists often observe reduced hematocrit associated with inhibitors of angiotensin-converting enzyme (ACE), the basis for this effect is not well understood. We now report that two strains of ACE knockout mice have a normocytic anemia associated with elevated plasma erythropoietin levels. (51)Cr labeling of red cells showed that the knockout mice have a normal total blood volume but a reduced red cell mass. ACE knockout mice, which lack tissue ACE, are anemic despite having normal renal function. These mice have increased plasma levels of the peptide acetyl-SDKP, a possible stem cell suppressor. However, they also show low plasma levels of angiotensin II. Infusion of angiotensin II for 2 weeks increased hematocrit to near normal levels. These data suggest that angiotensin II facilitates erythropoiesis, a conclusion with implications for the management of chronically ill patients on inhibitors of the renin-angiotensin system.
Collapse
Affiliation(s)
- J Cole
- Department of Pathology, Emory University, Atlanta, Georgia, USA. Institute National de la Santé et de la Recherche Medicale Unit 36, College de France, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Capecchi M, Ficarra G, Pagni L. [Benign pemphigoid of the mucous membranes: the clinical and histopathological aspects in 20 patients]. Minerva Stomatol 1994; 43:423-428. [PMID: 7816017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Benign mucous membrane pemphigoid is an autoimmune vesiculo-bullous disease which affects the oral mucosa. The purpose of this study is to report the clinical and pathological features of 20 patients with benign mucous membrane pemphigoid. Four patients were men and 16 female with a mean age of 58 years. The ratio of male to female was 1:4. Seventy percent of patients showed gingival involvement. Other locations were buccal mucosa, palate and floor of the mouth. The majority of patients had ulcers covered by pseudomembranes, complained of pain and burning and 40% reported bleeding gums. Nikolsky's sign was observed in 60% of cases. In all cases microscopic features of benign mucous membrane pemphigoid showed a separation of epithelium from the connective tissue along the basement membrane (sub-epithelial bulla).
Collapse
Affiliation(s)
- M Capecchi
- Istituto di Odonto-Gnato-Stomatologia, USL 10/D, Università di Firenze
| | | | | |
Collapse
|
8
|
|
9
|
|
10
|
Abstract
Transfer RNA (tRNA) suppression of nonsense mutations in prokaryotic systems has been widely used to study the structure and function of different prokaryotic genes. Through genetic engineering techniques, it is now possible to introduce suppressor (Su+) tRNA molecules into mammalian cells. A quantitative assay of the suppressor tRNA activity in these mammalian cells is described; it is based on the amount of tRNA-mediated readthrough of a terminating codon in the influenza virus NS1 gene after the cells are infected with virus. Suppressor activity in L cells continuously expressing Su+ (tRNAtyr) was 3.5 percent and that in CV-1 cells infected with an SV40- Su+ (tRNAtyr) recombinant was 22.5 percent.
Collapse
|